MRKR (Marker Therapeutics) Total Liabilities: $3.64 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MRKR Marker Therapeutics Inc MRKR
30 GF Score
Price $1.34
! 1 Warning Sign
View Full Analysis

What is Marker Therapeutics Total Liabilities?

Marker Therapeutics MRKR -4.96% 30 Total Liabilities is $3.64 Mil as of Mar. 2026. GuruFocus rates MRKR with a GF Score™ of 30/100. The stock has 1 warning sign investors should review.

Marker Therapeutics's Total Liabilities for the quarter that ended in Mar. 2026 was $3.64 Mil.

Marker Therapeutics's quarterly Total Liabilities declined from Sep. 2025 ($3.35 Mil) to Dec. 2025 ($2.27 Mil) but then increased from Dec. 2025 ($2.27 Mil) to Mar. 2026 ($3.64 Mil).

Marker Therapeutics's annual Total Liabilities increased from Dec. 2023 ($3.08 Mil) to Dec. 2024 ($3.46 Mil) but then declined from Dec. 2024 ($3.46 Mil) to Dec. 2025 ($2.27 Mil).

Marker Therapeutics Total Liabilities Historical Data

* Premium members only.

The historical data trend for Marker Therapeutics's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Marker Therapeutics Total Liabilities Chart

Marker Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 24.15 14.82 3.08 3.46 2.27

Marker Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.50 4.28 3.35 2.27 3.64
MRKR
30GF Score
Marker Therapeutics Inc MRKR
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Marker Therapeutics Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Marker Therapeutics's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=2.274+(0+0
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=2.27

Total Liabilities=Total Assets (A: Dec. 2025 )-Total Equity (A: Dec. 2025 )
=19.071-16.797
=2.27

Marker Therapeutics's Total Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=3.638+(0+0
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=3.64

Total Liabilities=Total Assets (Q: Mar. 2026 )-Total Equity (Q: Mar. 2026 )
=17.434-13.796
=3.64

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of $3.64 Mil mean?
Marker Therapeutics (MRKR) has a Total Liabilities of $3.64 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Marker Therapeutics and its competitors.
Is Marker Therapeutics' Total Liabilities too high?
Marker Therapeutics' current Total Liabilities is $3.64 Mil. Overall, Marker Therapeutics has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Marker Therapeutics' Total Liabilities compare to PLUR and VYNE?
Marker Therapeutics' Total Liabilities of $3.64 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Marker Therapeutics and its competitors. Marker Therapeutics's current Total Liabilities is $3.64 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Marker Therapeutics stock overvalued right now?
Marker Therapeutics (MRKR) has a current Total Liabilities of $3.64 Mil. The current Total Liabilities is $3.64 Mil. Marker Therapeutics' overall GF Score™ is 30/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Marker Therapeutics (MRKR), the current Total Liabilities is $3.64 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Marker Therapeutics Business Description

Other Exchanges GX1:Germany
Address 2450 Holcombe Boulevard, TMC Partners Office 1.311, Houston, TX, USA, 77021
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from MAR-T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells. These T cells are designed to recognize multiple tumor targets to produce broad spectrum anti-tumor activity. Its pipeline products include: Autologous MAR-T cell product for the treatment of lymphoma and pancreatic cancer (MT-601), and Off-the-Shelf (OTS) products (MT-401-OTS).
30GF Score

Get the complete analysis for MRKR

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.34
Price